Real-world study of ibrutinib for relapsed/refractory mantle cell lymphoma

  • Tucker D & al.
  • Br J Haematol
  • 23 May 2020

  • curated by Dawn O'Shea
  • Medical news
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

The Bruton’s tyrosine kinase inhibitor (BTKi) ibrutinib has emerged as possibly the most effective and well-tolerated of the novel agents in the management of relapsed and refractory (r/r) mantle cell lymphoma (MCL). Pooled 7.5-year survival data from clinical trials show five-year progression-free (PFS) and overall survival (OS) of 19% and 41%, respectively. However, until now, long-term data to compare real-world with clinical trial outcomes has been lacking.

Published in the British Journal of Haematology this week is a five-year real-world observational study of survival and tolerability of ibrutinib monotherapy in 65 patients with r/r MCL at 37 hospitals across the UK and Ireland as part of the Janssen-Cilag Named Patient Programme (NPP) which ran from November 2014 to December 2015.

The median progression-free survival (PFS) and overall survival (OS) was found to be 12 and 18.5 months, respectively. Ibrutinib was well-tolerated with no fatal adverse events.

Overall, 80% of patients discontinued treatment, predominantly due to disease progression. On discontinuation, 20% received alternative immunochemotherapy with a median OS of 24 months.

Ibrutinib was used as a bridge to transplant in 8% (median OS not reached).

The observations are comparable with trial outcomes, with encouraging responses to immunochemotherapy at relapse.